ARCHIVES

Ceritinib Demonstrates 58% ORR, 7-month PFS in ALK+ NSCLC

This article is from The Cancer Letter archive.

Vol. 37 No. 3 | March 28, 2014

Download PDF Visit The Full Archive

Related Articles

Johnson, Katterhagen Applaud CCOP RFA But With It Had Money For More Cancer Control

July 30, 1982

NIH Human Connectome Project To Map Brain Connections

July 31, 2009

Drug Combination Can Block Proteins Preventing Cell Death In Acute Lymphoblastic Leukemia

September 27, 2013

New Jersey Legislature Votes to Oppose USPSTF PSA Screening Downgrade

January 20, 2012

DCPC Advisors Okay Omnibus Prevention Program Announcement

January 24, 1992

Perifosine Fails Primary Endpoint, Zentaris CEO Explores Options

April 27, 2012